Dermata Therapeutics, Inc. (DRMA)
After hours:
- ACCESSWIRE
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
/ Dermata Therapeutics, Inc. ("Dermata" or the "Company") (Nasdaq:DRMA)(DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced topline results from its Phase 2 trial of once-weekly topical application of DMT310 for the treatment of moderate-to-severe rosacea.
- ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Dermata Therapeutics, Inc. (Nasdaq:DRMA;DRMAW) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022.
- ACCESSWIRE
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.
